79 related articles for article (PubMed ID: 9726103)
1. Camptothecin radiation sensitization: mechanisms, schedules, and timing.
Rich TA; Kirichenko AV
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):114-20. PubMed ID: 9726103
[TBL] [Abstract][Full Text] [Related]
2. Camptothecin schedule and timing of administration with irradiation.
Rich TA; Kirichenko AV
Oncology (Williston Park); 2001 Mar; 15(3 Suppl 5):37-41. PubMed ID: 11301839
[TBL] [Abstract][Full Text] [Related]
3. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
Jung LL; Zamboni WC
Drug Resist Updat; 2001 Jun; 4(3):152-67. PubMed ID: 11768329
[TBL] [Abstract][Full Text] [Related]
4. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
Garcia-Carbonero R; Supko JG
Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
[TBL] [Abstract][Full Text] [Related]
5. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
Jung LL; Zamboni WC
Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin.
Kirichenko AV; Rich TA; Newman RA; Travis EL
Cancer Res; 1997 May; 57(10):1929-33. PubMed ID: 9157987
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase I-targeting drugs as radiation sensitizers.
Chen AY; Choy H; Rothenberg ML
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
[TBL] [Abstract][Full Text] [Related]
8. Radiation enhancement by 9-aminocamptothecin: the effect of fractionation and timing of administration.
Kirichenko AV; Rich TA
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):659-64. PubMed ID: 10348297
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
O'Leary JJ; Shapiro RL; Ren CJ; Chuang N; Cohen HW; Potmesil M
Clin Cancer Res; 1999 Jan; 5(1):181-7. PubMed ID: 9918217
[TBL] [Abstract][Full Text] [Related]
10. Camptothecins: a review of their development and schedules of administration.
O'Leary J; Muggia FM
Eur J Cancer; 1998 Sep; 34(10):1500-8. PubMed ID: 9893620
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
[TBL] [Abstract][Full Text] [Related]
12. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
De Cesare M; Pratesi G; Perego P; Carenini N; Tinelli S; Merlini L; Penco S; Pisano C; Bucci F; Vesci L; Pace S; Capocasa F; Carminati P; Zunino F
Cancer Res; 2001 Oct; 61(19):7189-95. PubMed ID: 11585754
[TBL] [Abstract][Full Text] [Related]
13. Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs.
Voeller DM; Grem JL; Pommier Y; Paull K; Allegra CJ
Cancer Chemother Pharmacol; 2000; 45(5):409-16. PubMed ID: 10803925
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of camptothecins.
Iyer L; Ratain MJ
Cancer Chemother Pharmacol; 1998; 42 Suppl():S31-43. PubMed ID: 9750027
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of UV-A-induced cytotoxicity to cancer cell lines by camptothecin.
Kojima S; Fujishima H; Wang DS
Anticancer Res; 1997; 17(1A):241-6. PubMed ID: 9066659
[TBL] [Abstract][Full Text] [Related]
16. Review camptothecin: current perspectives.
Li QY; Zu YG; Shi RZ; Yao LP
Curr Med Chem; 2006; 13(17):2021-39. PubMed ID: 16842195
[TBL] [Abstract][Full Text] [Related]
17. [Camptothecin and derivatives: a new class of antitumor agents].
Torck M; Pinkas M
J Pharm Belg; 1996; 51(4):200-7. PubMed ID: 8965250
[TBL] [Abstract][Full Text] [Related]
18. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
19. Clinical applications of the camptothecins.
Takimoto CH; Wright J; Arbuck SG
Biochim Biophys Acta; 1998 Oct; 1400(1-3):107-19. PubMed ID: 9748525
[TBL] [Abstract][Full Text] [Related]
20. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.
Hoki Y; Fujimori A; Pommier Y
Cancer Chemother Pharmacol; 1997; 40(5):433-8. PubMed ID: 9272121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
